Coeptis Therapeutics Approved for Nasdaq Listing

Coeptis Therapeutics announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and the Company will change its corporate name to Z Squared Inc. The new listing application approval follows the satisfaction of other key closing conditions to the proposed merger, including effectiveness of the Company's registration statement on Form S-4 and shareholder approval of the merger proposals at the Company's January 30, 2026 stockholders' meeting. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis, and the Company will change its corporate name to Z Squared Inc. The transaction remains subject to satisfaction of any remaining customary closing conditions, and there can be no assurance that such conditions will be satisfied. The transaction is expected to close in Q2 2026.